Renal Anemia Treatment

Global Renal Anemia Treatment Market to Reach US$10.5 Billion by 2030

The global market for Renal Anemia Treatment estimated at US$7.8 Billion in the year 2024, is expected to reach US$10.5 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Medication Treatment, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$6.7 Billion by the end of the analysis period. Growth in the Dietary Supplement Treatment segment is estimated at 3.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.1 Billion While China is Forecast to Grow at 8.4% CAGR

The Renal Anemia Treatment market in the U.S. is estimated at US$2.1 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Renal Anemia Treatment Market - Key Trends & Drivers Summarized

Why Is Renal Anemia Emerging as a Critical Comorbidity in Chronic Kidney Disease?
Renal anemia, a common complication of chronic kidney disease (CKD), is primarily caused by the kidneys’ reduced ability to produce erythropoietin, the hormone essential for red blood cell synthesis. As CKD progresses, impaired erythropoietin production leads to decreased hemoglobin levels, causing fatigue, cardiovascular strain, and diminished quality of life. The prevalence of renal anemia increases with the severity of CKD, affecting nearly 90% of patients in stage 5. This correlation has brought renewed clinical focus on early detection and integrated management of anemia in CKD to prevent long-term systemic complications.

Managing renal anemia is particularly challenging because of the interplay between iron deficiency, inflammation, and erythropoiesis-stimulating agent (ESA) resistance. Inflammation and elevated hepcidin levels restrict iron mobilization, further suppressing erythropoiesis. Cardiovascular risks associated with high ESA doses and iron overload have also influenced the evolution of treatment protocols. These complexities have prompted nephrologists to favor individualized treatment approaches that balance efficacy, safety, and quality of life. The increasing global burden of CKD-linked to aging populations, diabetes, and hypertension-is fueling the expansion of the renal anemia treatment market.

How Are Treatment Modalities Evolving With Technological and Clinical Innovations?
Historically, renal anemia has been treated using ESAs and intravenous (IV) iron supplementation. First-generation ESAs such as epoetin alfa and darbepoetin alfa became standard therapy, stimulating erythropoiesis in dialysis and non-dialysis patients. However, long-term data revealing elevated cardiovascular risks with high ESA doses, particularly in non-dialysis CKD patients, have driven the development of safer and more physiologic alternatives. One such innovation is the class of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), which stimulate endogenous erythropoietin production at physiological levels while improving iron utilization.

Approved HIF-PHIs such as roxadustat, daprodustat, and vadadustat are oral agents offering a non-injectable alternative to ESAs. These drugs have demonstrated comparable efficacy in increasing hemoglobin levels, with additional benefits in reducing hepcidin and improving iron metabolism. They are especially suited for non-dialysis CKD patients who might otherwise face adherence issues with injectable ESAs. IV iron formulations have also advanced, with newer agents such as ferric carboxymaltose and ferric derisomaltose offering larger single-dose administration and reduced infusion frequency. The combination of these innovations is shifting treatment paradigms away from ESA-centric regimens toward more holistic and targeted approaches.

Which Patient Populations and Healthcare Settings Are Driving Demand Differentiation?
Dialysis-dependent patients form the core segment of the renal anemia treatment market. Hemodialysis facilities maintain consistent ESA and IV iron protocols due to the high anemia burden in this population. However, the non-dialysis CKD population, which is substantially larger in absolute numbers, is emerging as a major area of unmet need. These patients are less likely to be monitored regularly, and logistical challenges associated with injectable therapies often delay anemia intervention. Oral HIF-PHIs are being positioned as game changers for this segment due to their convenience and better adherence potential.

Pediatric CKD patients represent a niche but significant subset. Anemia management in this population requires weight-adjusted dosing and heightened vigilance for long-term adverse effects, driving demand for safer formulations and long-acting agents. Geographically, high-growth markets include China, India, and Latin America, where CKD incidence is rising and healthcare systems are expanding access to dialysis and nephrology care. In these regions, biosimilars and cost-effective oral therapies are gaining traction. Meanwhile, North America and Europe continue to invest in treatment innovation and care integration, with reimbursement frameworks adapting to support new therapeutic classes.

What Factors Are Driving the Growth of the Renal Anemia Treatment Market?
The growth in the renal anemia treatment market is driven by the global rise in CKD prevalence, clinical adoption of novel therapeutics such as HIF-PHIs, improved anemia screening programs, and expanding dialysis infrastructure. Aging populations, rising diabetes and hypertension rates, and environmental contributors to kidney disease are steadily increasing the global patient pool. This is translating into higher demand for long-term anemia management, particularly in pre-dialysis and elderly populations.

Regulatory approvals for oral HIF-PHIs across major markets are enhancing treatment accessibility and patient adherence. Health systems are gradually adopting value-based care models that prioritize early anemia intervention to reduce cardiovascular complications and hospitalizations. Technological advancements in point-of-care hemoglobin monitoring and iron profiling are improving diagnosis and real-time treatment adjustment. Reimbursement reforms, particularly in the U.S. under the ESRD Treatment Choices Model, are also incentivizing better anemia control in dialysis centers. Together, these trends are reshaping a market that was once dominated by injectables into one that is more diverse, patient-centric, and innovation-driven.

SCOPE OF STUDY:

The report analyzes the Renal Anemia Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Treatment (Medication Treatment, Dietary Supplement Treatment); Disease (Normocytic Anemia Disease, Microcytic Anemia Disease, Macrocytic Anemia Disease)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• AbbVie Inc.
• Akebia Therapeutics, Inc.
• Amgen Inc.
• Asahi Kasei Corporation
• Astellas Pharma Inc.
• AstraZeneca plc
• Baxter International Inc.
• Bayer AG
• B. Braun Melsungen AG
• Boehringer Ingelheim GmbH
• CSL Vifor
• DaVita Inc.
• Eli Lilly and Company
• FibroGen, Inc.
• Fresenius Medical Care AG & Co. KGaA
• GlaxoSmithKline (GSK) plc
• Japan Tobacco Inc.
• Johnson & Johnson
• Novartis AG
• Pfizer Inc.
• Roche (F. Hoffmann-La Roche Ltd.)
• Sanofi
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Zydus Lifesciences Ltd.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more